Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;122(1):212-5.
doi: 10.1016/j.ophtha.2014.10.012. Epub 2014 Nov 18.

Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test?

Emily Y Chew  1 , Michael L Klein  2 , Traci E Clemons  3 , Elvira Agrón  4 , Gonçalo R Abecasis  5
Affiliations

Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test?

Emily Y Chew et al. Ophthalmology. 2015 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Study was sponsored by the NIH. The NIH holds a royalty-bearing license issued to Bausch and Lomb for the Age-Related Eye Disease Study Supplement. Dr. Abecasis received royalties from patents held by University of Michigan. None of the other authors have financial disclosure.

Figures

Figure 1
Figure 1
shows the Hazard Ratios for the progression to late age-related macular degeneration for each of the components of the Age-Related Eye Disease Study (AREDS) supplement: antioxidant, zinc, combination of antioxidant and zinc vs. placebo in the analyses reported by Awh et al and the results of the replication of the analyses in the residual cohort of AREDS participants. These are stratified by the genotype treatment groups defined by the Awh et al publication. Figure 1a–c are the four genotype treatment groups. Note the differences seen in Figures 1a and 1b where beneficial effect of the combination of antioxidant and zinc is greater in the analyses conducted in the residual cohort. The harmful effects of genotype treatment group 2 (figure 1b) in the Awh analyses were not replicated in the analyses conducted on the residual cohort. Figure 1e is stratified by astrological signs, using outcomes for the basis of the subgrouping. Using the Awh cohort, we found a harmful effect of zinc in those born under the birth signs of Aries and Cancer. The analysis in the residual cohort demonstrated a beneficial effect with zinc, demonstrating the important of replication in studies of genetic associations.
See this image and copyright information in PMC

Comment in

References

    1. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417–36. - PMC - PubMed
    1. Klein ML, Francis PJ, Rosner B, et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology. 2008;115:1019–25. - PubMed
    1. Awh CC, Lane AM, Hawken S, et al. CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology. 2013;120:2317–23. - PubMed
    1. Chew EY, Klein M, Clemons TE, et al. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements. AREDS Report Number 38. Ophthalmology. 2014 Jun 26; pii: S0161-6420(14)00428-X. doi: 10.1016/j.ophtha.2014.05.008. [Epub ahead of print] - PMC - PubMed
    1. Awh C, Hawkin S, Zanke B. Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study. Ophthalmology. 2014 Aug; (in press) - PubMed

Publication types